Observational studyInterdisciplinary cardiovascular and thoracic surgery2025
Hybrid Atrial Fibrillation Ablation: Association of Clinical Characteristics, Biomarkers, and Blanking Period with Recurrence.
Observational study in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02516033 (Identification of a Risk Profile Associated With Failure of the Hybrid Ablation of Atrial Fibrillation.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification of a Risk Profile Associated With Failure of the Hybrid Ablation of Atrial Fibrillation.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesHybrid atrial fibrillation (AF) ablation is a treatment for therapy-resistant, symptomatic AF. Limited data exist on the risk factors for failure of the procedure. Therefore, this study aimed to identify clinical factors and blood biomarkers associated with atrial arrhythmia recurrence within 2 years following hybrid ablation.
methodsThe hybrid AF ablation study is a single-centre, prospective, observational study including consecutive AF patients who underwent hybrid ablation between January 2015 and September 2021. Blood samples were collected pre-ablation, and 7 biomarkers were assessed based on their possible association with recurrence. The blanking period was defined as the first 3 months after ablation. Clinical follow-up visits combined with 12-lead electrocardiogram (ECG) and 72-hour Holter monitoring were scheduled at 3, 6, 12, and 24 months post-procedure. Cox proportional hazard regression analyses were performed to assess the association with recurrence.
resultsOf the 91 patients included (mean age 57.1 years [standard deviation: 8.1]; 16% women), 31 (34%) experienced atrial arrhythmia recurrence within 2 years following hybrid ablation, with a median time to recurrence of 254 days (interquartile range 147-428). Multivariable Cox proportional hazard regression, adjusted for age and sex, showed that recurrence in the blanking period was associated with atrial arrhythmia recurrence within 2 years post-ablation (hazard ratio 4.05, 95% confidence interval 1.85-8.91); however, no association was detected between other clinical factors or blood biomarkers and atrial arrhythmia recurrence.
conclusionsIn AF patients undergoing hybrid ablation, recurrence in the blanking period was associated with atrial arrhythmia recurrence within 2 years post-ablation. CLINICAL REGISTRATION: ClinicalTrials.gov, NCT02516033, https://clinicaltrials.gov/ct2/show/NCT02516033.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.